Is Merck Less Bullish on Biosimilars?
This article was originally published in RPM Report
Executive Summary
Of all the Big Pharma manufacturers, none seemed more optimistic about the commercial potential of biosimilars than Merck. But over the last several months, Merck shut down its BioVentures Group and skipped an FDA public meeting on the abbreviated approval pathway. Has Merck soured on biosimilars?
You may also be interested in...
Hanwha Biologics CEO Paul Coleman On Developing Biosimilars In Korea: An Interview With PharmAsia News (Part 1 of 2)
The former Biogen Idec exec sits down to talk about Hanwha’s biosimilars strategy and pipeline, and why its deal fell apart with Merck to develop a biosimilar of Enbrel.
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.
Merck Partners With Korea’s Samsung Bioepis On Multiple Biosimilar Targets
Samsung Bioepis will be responsible for development, manufacturing and registration, while Merck will be responsible for commercializing any resulting drugs. Merck says the partnership will complement the firm’s internal biologics portfolio.